Literature DB >> 17948283

Lung disease severity, chronic inflammation, iron deficiency, and erythropoietin response in adults with cystic fibrosis.

R Fischer1, R Simmerlein, R M Huber, H Schiffl, S M Lang.   

Abstract

Chronic lung disorders are usually associated with a hypoxia driven increase in red cell mass. However, patients with cystic fibrosis (CF) often have normal or decreased haemoglobin levels. The present prospective observational study in cystic fibrosis patients was performed to determine which factors were involved in alterations in the hematopoetic response to corresponding arterial oxygen pressure. Sixty adult patients (age 21-51) with stable CF were included. They all had vitamin A, D, E, and K but no vitamin B12 supplementation. Twenty-five patients were on oral Fe(2+) (100 mg/day). Resting arterial blood gases, lung function, complete blood counts, parameters of iron status, CRP, sputum microbiology and serum erythropoietin were measured at recruitment and after 3 and 6 months. Patients had varying degrees of pulmonary functional impairment and 9% were hypoxemic (arterial oxygen pressure <60 mm Hg). Low-grade systemic inflammation (CRP > 0.5 mg/dl) was present in 40% of the patients, who all had bacterial colonization. None of the patient had erythrocytosis and 12 patients had anemia. There was no significant difference in iron status between patients with or without chronic iron supplementation and erythropoietin levels were normal. During the 6 months observation period no significant changes occurred. The patients exhibited an impaired erythropoietic response to hypoxemia with normal or low hematocrit in spite of chronic lung disease which might be caused by chronic inflammation associated with CF. Linear multivariate regression analysis revealed CRP levels but neither iron substitution, nor erythropoietin levels nor lung function parameters as independent determinant of haemoglobin levels. CF may be associated with anemia of variable severity as expression of the chronic inflammation present in these patients. The therapeutic consequences are to treat the underlying inflammation rather than to supplement iron.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17948283     DOI: 10.1002/ppul.20717

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  16 in total

1.  Iron supplementation does not worsen respiratory health or alter the sputum microbiome in cystic fibrosis.

Authors:  Alex H Gifford; Diana M Alexandru; Zhigang Li; Dana B Dorman; Lisa A Moulton; Katherine E Price; Thomas H Hampton; Mitchell L Sogin; Jonathan B Zuckerman; H Worth Parker; Bruce A Stanton; George A O'Toole
Journal:  J Cyst Fibros       Date:  2013-12-13       Impact factor: 5.482

Review 2.  Nutritional immunity: the impact of metals on lung immune cells and the airway microbiome during chronic respiratory disease.

Authors:  Claire Healy; Natalia Munoz-Wolf; Janné Strydom; Lynne Faherty; Niamh C Williams; Sarah Kenny; Seamas C Donnelly; Suzanne M Cloonan
Journal:  Respir Res       Date:  2021-04-29

3.  Iron and CF-related anemia: expanding clinical and biochemical relationships.

Authors:  A H Gifford; S D Miller; B P Jackson; T H Hampton; G A O'Toole; B A Stanton; H W Parker
Journal:  Pediatr Pulmonol       Date:  2010-10-20

4.  Postmortem serum erythropoietin levels in establishing the cause of death and survival time at medicolegal autopsy.

Authors:  L Quan; B-L Zhu; T Ishikawa; T Michiue; D Zhao; D-R Li; M Ogawa; H Maeda
Journal:  Int J Legal Med       Date:  2008-08-06       Impact factor: 2.686

5.  Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells.

Authors:  Sophie Moreau-Marquis; George A O'Toole; Bruce A Stanton
Journal:  Am J Respir Cell Mol Biol       Date:  2009-01-23       Impact factor: 6.914

6.  Use of proton pump inhibitors is associated with lower hemoglobin levels in people with cystic fibrosis.

Authors:  Alex H Gifford; Julie L Sanville; Meghana Sathe; Sonya L Heltshe; Christopher H Goss
Journal:  Pediatr Pulmonol       Date:  2021-04-26

7.  CFTR Modulator Use Is Associated with Higher Hemoglobin Levels in Individuals with Cystic Fibrosis.

Authors:  Alex H Gifford; Sonya L Heltshe; Christopher H Goss
Journal:  Ann Am Thorac Soc       Date:  2019-03

8.  Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron.

Authors:  Donald S Silverberg; Ram Mor; Melanie Tia Weu; Doron Schwartz; Idit F Schwartz; Gil Chernin
Journal:  BMC Pulm Med       Date:  2014-02-24       Impact factor: 3.317

9.  Exercise oxidative skeletal muscle metabolism in adolescents with cystic fibrosis.

Authors:  Maarten Werkman; Jeroen Jeneson; Paul Helders; Bert Arets; Kors van der Ent; Birgitta Velthuis; Rutger Nievelstein; Tim Takken; Erik Hulzebos
Journal:  Exp Physiol       Date:  2016-03       Impact factor: 2.969

10.  A cross-sectional study of the prevalence and associations of iron deficiency in a cohort of patients with chronic obstructive pulmonary disease.

Authors:  Annabel H Nickol; Matthew C Frise; Hung-Yuan Cheng; Anne McGahey; Bethan M McFadyen; Tara Harris-Wright; Nicole K Bart; M Kate Curtis; Shivani Khandwala; David P O'Neill; Karen A Pollard; F Maxine Hardinge; Najib M Rahman; Andrew E Armitage; Keith L Dorrington; Hal Drakesmith; Peter J Ratcliffe; Peter A Robbins
Journal:  BMJ Open       Date:  2015-07-06       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.